Ontology highlight
ABSTRACT:
SUBMITTER: Fitzpatrick O
PROVIDER: S-EPMC8572112 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature
Fitzpatrick Orla O Naidoo Jarushka J
Lung Cancer (Auckland, N.Z.) 20211102
Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non-small cell lung cancer (NSCLC). This class of agents inhibits the interaction between PD1 and PDL1, and was shown to be efficacious in the landmark PACIFIC trial with 1 year of maintenance durvalumab (anti-PDL1 antibody). This trial demonstrated that its use as a consolidation treatment given after definitive chemoradiotherapy improved progression free survival and overall survi ...[more]